Skip to Content

Lonza Group Ltd LONN Stock Quote

| Rating as of

Morningstar‘s Stock Analysis LONN

Currency in CHF
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Maintaining CHF 620 Fair Value Estimate for Narrow-Moat Lonza; Shares Undervalued

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

Lonza Group has been a dominant player in the contract development and manufacturing space for decades. We think the outlook for Lonza looks bright, especially as drug manufacturing becomes more complex with biologics and cell and gene therapies playing larger roles in the overall mix.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LONN

Company Profile LONN

Business Description

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Muenchensteinerstrasse 38
Basel, CH-4002, Switzerland
T +41 613168111
Industry Diagnostics & Research
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Employees 17,154